Related Experiment Videos
Anaemia in chronic renal disease: lessons learned since Seville 1994
1Division of Nephrology, Memorial University, St John's, Newfoundland A1B 3V6, Canada.
Insights
Anemia correction in end-stage renal disease (ESRD) patients shows no cardiovascular benefit in trials for those with advanced heart conditions. Further research is needed to determine optimal hemoglobin targets for preventing cardiovascular complications in ESRD.
Area of Science:
- Nephrology
- Cardiology
- Hematology
Background:
- Cardiovascular disease (CVD) is the leading cause of death in end-stage renal disease (ESRD) patients.
- Anemia is prevalent in chronic kidney disease (CKD), affecting up to 90% of patients.
- Anemia's role in cardiovascular dysfunction in the uraemic population is increasingly understood.
Purpose of the Study:
- To evaluate the cardiovascular benefits of early anemia correction in ESRD patients.
- To investigate the impact of recombinant erythropoietin (rh-Epo) on cardiovascular outcomes.
- To identify appropriate hemoglobin targets for preventing cardiovascular comorbidities.
Main Methods:
- Analysis of randomized, controlled trials (RCTs) on anemia correction in haemodialysis patients.
- Assessment of cardiovascular outcomes in patients with symptomatic heart failure, ischaemic heart disease, or left ventricular dilatation.
- Review of existing evidence on the effects of anemia correction at different stages of cardiac disease.
Main Results:
- Normalization of hemoglobin (Hb) with rh-Epo showed no cardiovascular benefit in haemodialysis patients with established heart failure, ischaemic heart disease, or severe left ventricular dilatation.
- Suggestive evidence indicates potential benefits of anemia correction at earlier stages of cardiac disease.
- Large-scale clinical trials are needed to clarify effects on mortality and cardiovascular function.
Conclusions:
- Current evidence does not support anemia normalization for cardiovascular benefit in advanced heart disease among haemodialysis patients.
- Early anemia correction strategies require further investigation to establish efficacy and optimal targets.
- Higher hemoglobin levels may offer cardioprotective effects and potentially extend patient survival.
Abstract:
Cardiovascular disease is the major cause of death among patients with end-stage renal disease, accounting for almost half of all fatalities. In recent years much progress has been made in understanding the pathogenesis of cardiovascular disease in the uraemic population. Anaemia is a consistent finding in chronic renal disease, affecting up to 90% of patients, and the central role of anaemia in the development of cardiovascular dysfunction is now well established. A significant proportion of patients have established cardiovascular complications on initiation of dialysis, raising the possibility of early correction of anaemia as a strategy for preventing cardiovascular co-morbidities among renal patients. Randomized, controlled trials have shown that normalization of haemoglobin (Hb) with recombinant erythropoietin (rh-Epo) is of no cardiovascular benefit in haemodialysis patients with symptomatic heart failure, ischaemic heart disease, or severe left ventricular dilatation, although suggestive evidence exists for benefits at earlier stages of cardiac disease. Results from large-scale clinical trials are required to clarify the effects of early anaemia correction on mortality and cardiovascular function, as well as appropriate treatment targets in different patient populations. The potential exists for higher Hb levels to extend patient survival through cardioprotective effects.